Latham & Watkins Advised Leading Stem Cell Biotech Mesoblast On Refinancing Of Up To US$125 Million

Latham & Watkins Advised Leading Stem Cell Biotech Mesoblast on Refinancing of Up to US$125 Million

Latham & Watkins advised Mesoblast Limited (Nasdaq: MESO; ASX: MSB), a global leader in allogeneic cellular medicines for inflammatory diseases, on the refinancing of up to US$125 million. The transaction involved the full repayment of Mesoblast’s existing senior secured loan from Oaktree Capital Management, Inc., and a partial repayment of its subordinated royalty facility from NovaQuest Capital Management LLC.

The refinancing was effected through a new five-year facility provided by Mesoblast’s existing shareholder and director, Dr. Gregory George. Mesoblast drew down an initial tranche of US$75 million, with a second tranche of up to US$50 million available at the company’s option until June 30, 2026.

The Latham & Watkins LLP team led by Haim Zaltzman (Partner), with Hyunji Lee (Associate), and William Lane (Associate). Advice was also provided on tax matters by Eric Cho (Partner), with Sam Yang (Associate), and on UK finance matters by James Chesterman (Partner), with Chris Attrill (Associate), and Kathleen Teo (Associate).

Click to know more about Latham & Watkins

If you have a news or deal publication or would like to collaborate on content, columns, or article publications, connect with the Legal Era News Network Team and email us at info@legalera.in or call us on +91 8879634922.